Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics
about
Structural Proteomics of HerpesvirusesInhibitors of signal peptide peptidase (SPP) affect HSV-1 infectivity in vitro and in vivo.The suppression of apoptosis by α-herpesvirus.Cultured corneas show dendritic spread and restrict herpes simplex virus infection that is not observed with cultured corneal cells.O-linked glycosylation of the mucin domain of the herpes simplex virus type 1-specific glycoprotein gC-1 is temporally regulated in a seed-and-spread mannerAsymptomatic memory CD8+ T cells: from development and regulation to consideration for human vaccines and immunotherapeuticsComparative Analysis of the Antiviral Activity of Camel, Bovine, and Human Lactoperoxidases Against Herpes Simplex Virus Type 1.Early Viral Entry Assays for the Identification and Evaluation of Antiviral Compounds.Proteoglycan expression correlates with the phenotype of malignant and non-malignant EBV-positive B-cell lines.Regulation of T-type Ca(2+) channel expression by herpes simplex virus-1 infection in sensory-like ND7 cells.Comparison of three cell-based drug screening platforms for HSV-1 infection.HSV-1 interaction to 3-O-sulfated heparan sulfate in mouse-derived DRG explant and profiles of inflammatory markers during virus infection.Size-dependent inhibition of herpesvirus cellular entry by polyvalent nanoarchitectures.iPSC Neuronal Assay Identifies Amaryllidaceae Pharmacophore with Multiple Effects against Herpesvirus Infections.In vitro antiviral activity of plant extracts from Asteraceae medicinal plants.Systematic screening of viral entry inhibitors using surface plasmon resonance.In search for effective and definitive treatment of herpes simplex virus type 1 (HSV-1) infections
P2860
Q26767085-50846273-C865-49B4-AC1C-373001BC3CC2Q33717645-9184AD41-F8DD-490F-8B7F-5242F9E1F383Q33815866-15385301-820D-406E-8929-62BB239947DBQ34551257-BAFD1E59-657A-4BF0-A00E-BA0002C21A5FQ35104007-325E5A8B-B99F-449F-90F6-6E7749E91E31Q36977847-A3D260FB-81A1-4692-B134-A5EF1131DA68Q38730749-886D1E63-38BD-4F2E-8BC1-73F2A2A76566Q38820461-037B3AA0-43BE-496E-8700-65436903071AQ38822694-A00B017B-BB4B-442B-8B72-DECF9A5C8E48Q40150082-8E953630-B481-4A15-AACF-9163B9E2DA75Q40273624-B305108D-7181-4E23-94D9-4B806F113DEBQ40281690-71E48A16-9407-406B-B573-6B41410EB273Q40305340-65C5A5B9-5907-4E8B-8E48-B5E279342CECQ40814812-BB817D5E-6104-43C7-B2C7-8DD59ED8CC94Q42281127-BF1EF555-4FC6-429B-B235-EA506ED1A4D2Q44105945-0C280F51-71B5-4399-9EC6-12965D94D970Q56789970-EA7B7A6C-ADC6-4E94-AEE6-C3F101321EC8
P2860
Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics
@en
type
label
Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics
@en
prefLabel
Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics
@en
P2860
P356
P1476
Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics
@en
P2093
Paul J Park
Thessicar E Antoine
P2860
P304
P356
10.1002/RMV.1740
P577
2013-02-26T00:00:00Z